Clinical trials

  • Durvalumab for Non-small cell lung cancer (advanced/metastatic) | Non-small cell lung cancer (locally advanced, unresectable; Stage III) | Small-cell lung cancer (extensive disease, Stage IV) | Urothelial carcinoma of the urinary tract (post-chemotherapy)
  • Dapagliflozin for Membranous nephropathy
  • Human normal immunoglobulin (IV) for Chronic immune thrombocytopenia (ITP)
  • SELUMETINIB (selumetinib hyd-sulfate) for Neurofibromatosis type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas
  • 64CU-DOTA-AE105 for Prostate cancer
  • OCRELIZUMAB for Multiple sclerosis
  • MUNC-CD34 for Familial Hemophagocytic Lymphohistiocytosis (FHL)
  • Clinical trial in Locally advanced rectal cancer|Rectal cancer
  • Pneumococcal polysaccharide conjugate (multiple serotypes) for Prevention of pneumococcal disease
  • VIBRIO ALGINOLYTICUS COLLAGENASE for Dupuytren's contracture
  • POVETACICEPT for Autoimmune cytopenias | Warm autoimmune hemolytic anemia | Cold agglutinin disease | Immune thrombocytopenia
  • Antithrombin III (human) for Acquired antithrombin III deficiency | Heparin resistance